Company visit 'Spin-off'

What is it like to work for a spin-off company?

On 1 June PCDI and the Amsterdam BioMed Cluster are organising a

Life Sciences Company Visit

for you to find out.


What is it like to work for a spin-off company?


On 1 June PCDI and the Amsterdam BioMed Cluster are organising a Life Sciences Company Visit for you to find out. How are promising research projects turned into a business? What parties are involved and... what challenges are there for you, as a early career researcher, in the entire process from an idea to an established company?

PCDI and Amsterdam BioMed Cluster invite you to a workshop on technology transfer and careers at university spin-off companies. You will be given insights into the process of knowledge valorisation. The companies AIMM Therapeutics and Arthrogen will explain how spin-off companies function and what opportunities there may be for early career researchers like you. During a guided tour at Arthrogen, you can see by yourself what difference there are between a spin-off company and academia. A career at a young spin-off company, something to consider for your next career step?


The company visit will be interactive, fire all your questions at the presentations and network drinks.


15:30 - 16:10     Introduction
to knowledge valorisation
Joris Heus, TTO manager
AMC Technology Transfer Office
16:10 - 16:50 AIMM Therapeutics Willem van Oort, CEO
16:50 - 17:20 Arthrogen
introduction & guided tour        
Mark Lambermon, scientist
from 17:20 Network drinks colleagues from TTO AMC,
AIMM Therapeutics and Arthrogen


AMC in Spring



Life Sciences Company Visit


Tuesday 1 June 2010
15:30 – 18.00

Bureau Kennistransfer AMC
Meibergdreef 45
1105 AZ Amsterdam
For who? Postdocs and final year PhD students

Free of charge
but registration via PCDI is required

  Registration is now closed


Background information

AMC Technology Transfer Office

AMC Technology Transfer Office (aka Bureau Kennis Transfer) offers expert advice and guidance on the road to knowledge valorisation – taking your knowledge-intensive ideas and technologies to the market and society. Services are aimed at academics and other scientific personnel. Government offices and the private sector get in touch in search for cooperation with academia and to further their ideas through academic support and scientific research. The AMC Technology Transfer Office works at the intersection of academia, government and the private sector.

AIMM Therapeutics

AIMM’s portfolio is based on proprietary platform technologies for directed, fast and efficient development of fully human monoclonal antibodies. AIMM Therapeutics, a biotech company founded in 2004, focuses on the development of therapeutic proteins for the treatment of infections. This technology was first developed in the laboratory of Professor Hergen Spits, which was affiliated first to the NKI and later to the AMC. Many innovative products, targeting a wide range of viral and bacterial diseases as well as cancers, are under development at AIMM.


Arthrogen was founded in 2005 as a joint venture between the AMC and the Dubai Bones and Joints Hospital. The company focuses on the clinical and commercial development of an innovative gene therapy approach. This approach was first developed by researchers at the AMC as a cure for local rheumatoid arthritis of joints. The lead compound will enter phase-I trials in two years time.